By both boosting protective AAT for the lungs and potentially reducing hepatocyte stress from Z-AAT accumulation, WVE-006 offers a dual-organ disease-modifying strategy that could meaningfully improve outcomes for AATD patients if durability and clinical endpoints are confirmed in ongoing cohorts. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.